Owlin adds Consumer Sentiment & Review Data to its offering in its journey to transform risk management for Payment Service Providers
12.9.2023 16:00:00 EEST | Business Wire | Press release
Owlin, a global leader in merchant and third-party risk solutions, proudly announces its next big step in advancing the fintech industry: a new Consumer Review Data feature, specifically designed for Risk teams within Payment Service Providers (PSPs). Operational excellence becomes more important than ever for PSPs and manual review processes are often costly, reactive and inefficient. Owlin's latest offering heralds a transformative shift towards proactive, cost-effective, and highly efficient risk management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230912980645/en/
Owlin for Consumer Review Monitoring for Payment Service Providers (PSPs) (Photo: Business Wire)
One of the standout features of Owlin's Consumer Review Feature is its unparalleled ability to detect leading risk signals, such as signs of distress (e.g., delivery- or product issues) well ahead of bigger issues like a bankruptcy event. This capability provides PSPs with a significant advantage in proactively mitigating risk, preventing potential financial disasters, and safeguarding their operations and reputation.
Furthermore, Owlin's Consumer Review Feature is a significant advantage in the world of adverse media monitoring, helping improve merchant risk management. It builds upon Owlin's already world-class monitoring solution for PSPs and it gives PSPs the tools they need to stay competitive.
Key Features and Benefits:
- Real-time Feedback and Risk Alerts - Instantly gather consumer feedback and correlate it with advanced risk signals, alerting PSPs to potential risks well in advance.
- Advanced Analytics - Utilize AI-driven insights powered by large language models to gauge sentiment, track trends, and pinpoint areas requiring risk mitigation.
- Enhanced Engagement and Trust Building - Responsively address concerns, showcase negative reviews, risk mitigating actions, and fortify trust in the PSP ecosystem.
- In-depth Risk Profiles - Craft comprehensive risk profiles based on a blend of signals and consumer feedback, ensuring that risk management decisions are data-driven and merchant-centric.
Stefan Peekel, Chief Growth Officer at Owlin, remarks, “By integrating consumer review data into risk management practices, we're giving PSPs a comprehensive tool that's been absent in the industry. It's not just about enhancing services but also about fortifying them against threats. In essence we now equip PSPs with a magnifying glass and a map. While they get a detailed view of consumer sentiment on a merchant, they also see how signals interconnect, allowing them to preempt risks and capitalize on opportunities.’’
Dedicated to innovation, Owlin keeps pushing to redefine what is possible in the domain of risk management. With this latest consumer review offering Payment Service Providers are equipped with a new set of state of the art tools to manage risk effectively and build trust for merchants and consumers.
About Owlin
Owlin is an AI-driven Third Party Risk and Merchant Monitoring solution that helps businesses feed better and faster risk insights into daily risk management workflows in real time. Owlin applies AI and Natural Language Processing to provide valuable insights hidden in the data and ensures its users don’t get lost in the wealth of information by visualizing complex data in a simple and customizable interface.
For more information, visit https://owlin.com/solutions/consumer-review-monitoring/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912980645/en/
Contact information
Contact Owlin: Stefan Peekel, stefan@owlin.com, +1 201 932 4580
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom